MedTrace Logo

A Study Investigating the Efficacy and Safety of Ociperlimab and Tislelizumab and BAT1706 Combinations in Patients With Advanced HCC

NCT04948697 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 94

Last updated 2025-02-24

Study results available
· View outcomes & findings →

Summary

This was a Phase 2, randomized, multicenter, open-label, 2-arm study to investigate the efficacy and safety of ociperlimab in combination with tislelizumab plus BAT1706, and tislelizumab plus BAT1706, as first-line treatment in participants with advanced Hepatocellular Carcinoma (HCC).

Conditions

Interventions

DRUG

Ociperlimab

900 mg intravenously once every 3 weeks (dosed in 21-day cycles)

DRUG

Tislelizumab

200 mg intravenously once every 3 weeks (dosed in 21-day cycles)

DRUG

BAT1706

15 mg/kg intravenously once every 3 weeks (dosed in 21-day cycles)

Sponsors & Collaborators

  • BeiGene

    lead INDUSTRY

Principal Investigators

  • Study Director · BeiGene

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-20
Primary Completion
2024-02-01
Completion
2024-02-01

Countries

  • China
  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04948697 on ClinicalTrials.gov